Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

PAR-25-114: CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)

Closed Closed May 30, 2025 Opportunity PAR-25-114

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.

National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $275,000 in total. Applications closed on May 30, 2025.

From the official notice on Grants.gov, last changed October 25, 2024. Checked November 7, 2026.

About this NIH notice

Projects funded under PAR-25-114 were run by National Institute of Neurological Disorders and Stroke (NINDS, 3 projects), National Eye Institute (NEI, 2 projects), National Institute of Environmental Health Sciences (NIEHS, 2 projects) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read PAR-25-114 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
PAR-23-139March 22, 2023Closed October 24, 2024Closed

Key dates

PostedOctober 24, 2024
DeadlineMay 30, 2025
Archived by Grants.govJuly 5, 2025

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

This Notice of Funding Opportunity (NOFO) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. This NOFO supports translational research that includes, but is not limited to, preliminary efficacy and/or early preclinical development studies towards discovery and validation of novel molecular entities or biologics as candidate MCMs. In addition to novel agents, new treatment strategies may involve repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects supported by this NOFO are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement program and/or other related initiatives.

Category: Education, Environment, Health.

Funded under PAR-25-114 so far

NIH funded 9 projects under PAR-25-114 in fiscal 2026, at 8 institutions. The median yearly award was $426,250.

Most projects: University of Alabama at Birmingham (Alabama), 2, Wake Forest University Health Sciences (North Carolina), 1, Old Dominion University (Virginia), 1, University of Colorado Denver (Colorado), 1, Texas A&m University Health Science Ctr (Texas), 1.

Recently funded projects
ProjectInstitutionFiscal yearAward
PEDF-enriched Urine-derived Stem Cell Sheets for Corneal Wound Healing in Mustard Gas Injury R21Wake Forest University Health Sciences2026$426,250
2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury R21Old Dominion University2026$458,144
Therapeutic potential for NPS-2143 as treatment for chlorine induced lung edema R21University of Alabama at Birmingham2026$409,750
Translational Approaches for Ocular Injuries R21University of Colorado Denver2026$429,000
2-Deoxyglucose Therapy for Organophosphate Intoxication R21Texas A&m University Health Science Ctr2026$423,500
Opioids promote wound healing in vesicant induced skin injury R21Rutgers Biomedical and Health Sciences2026$431,750
Preclinical Development of Oleoylethanolamide as a Medical Countermeasure for Long-Term Neurotoxicity Following Organophosphate Exposure R21Roskamp Institute, Inc.2026$468,875
cGas-STING pathway based medical countermeasure for vesicant skin injury R21University of Alabama at Birmingham2026$408,374

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Allergy and Infectious Diseases Research grants before

From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
Fred Hutchinson Cancer CenterWashington85$938 million
Duke UniversityNorth Carolina230$781 million
University of California, Los AngelesCalifornia138$745 million
The Johns Hopkins UniversityMaryland321$668 million
Emory UniversityGeorgia282$650 million

Top states: California ($3.4 billion), Massachusetts ($2.1 billion), Washington ($1.9 billion), New York ($1.8 billion), North Carolina ($1.5 billion).

Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before

From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The General Hospital CorporationMassachusetts203$288 million
The Regents of the University of California, San FranciscoCalifornia248$277 million
The Johns Hopkins UniversityMaryland230$276 million
The Trustees of Columbia University in the City of New YorkNew York188$226 million
Regents of the University of MichiganMichigan179$221 million

Top states: California ($1.4 billion), New York ($926 million), Massachusetts ($906 million), Pennsylvania ($626 million), Texas ($499 million).

Who has won Drug Use and Addiction Research Programs grants before

From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
Yale UnivConnecticut150$305 million
The Johns Hopkins UniversityMaryland156$262 million
University of California, San DiegoCalifornia120$242 million
University of Pittsburgh - of the Commonwealth System of Higher EducationPennsylvania100$182 million
New York UniversityNew York62$173 million

Top states: California ($1.1 billion), New York ($773 million), Massachusetts ($613 million), Pennsylvania ($488 million), Maryland ($434 million).

Other programs behind this notice

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is PAR-25-114 still open?

No. It closed on May 30, 2025.

Who can apply for CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)?

Closed May 30, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

How much funding is available?

Awards of up to $275,000 each. About $275,000 in total.

Who has been funded under PAR-25-114?

NIH RePORTER lists 9 projects funded under PAR-25-114 in fiscal 2026, at 8 institutions. The most were at University of Alabama at Birmingham, Wake Forest University Health Sciences, Old Dominion University.

Who has won Environmental Health grants before?

The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.

Similar open grants